Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time on its sole clinical-stage candidate ...

The CD22-directed CAR-T, which was being tested in the FIRCE-1 study as a treatment for patients with relapsed/refractory large B-cell lymphoma (LBCL), was halted in January, with CARGO saying it ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia ... Researchers turned to an alternative marker, CD22, in an effort to expand ...

Research and Development (R&D) Expenses: R&D expenses were $26.6 million for the three months ended March 31, 2025, compared to $23.4 million for the same period in 2024. The increase in R&D expenses ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary cancers.